Trials / Completed
CompletedNCT06742736
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE INITIATING BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL (MITOS: EROS+CP US Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13,000 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGF | BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL |
Timeline
- Start date
- 2024-05-31
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2024-12-19
- Last updated
- 2025-08-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06742736. Inclusion in this directory is not an endorsement.